Lessons for the US on Biosimilar Pricing
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
Problems viewing this email?
Friday, December 9, 2022 | The Latest Research, Commentary, And News From Health Affairs
Dear John,

This week, we announced a partnership agreement with Oxford University Press (OUP) to publish Health Affairs Scholar, a new open access journal of emerging and global health policy. Read more about the new journal here.
Biosimilar Pricing
In a new Health Affairs article, James Robinson discusses lessons for the US from Germany’s therapeutic reference pricing for anti-inflammatory biosimilars.

Robinson explains that the German experience demonstrates that a redesign of consumer cost sharing that can achieve savings for payers without creating onerous financial barriers for patients.

Savings would be achieved by shifting cost sharing from coinsurance to “low copayments for affordable products and high copayments for products bearing higher prices without offering superior performance,” Robinson finds.

Robinson has published several articles about drug pricing and related topics which you can read on our website. He's also appeared on an episode of A Health Podyssey  to discuss innovations in biosimilars.
Advertisement
Elsewhere At Health Affairs
Today on Forefront, LaCinda Jones and coauthors indicate that elder mistreatment, also referred to as elder abuse, is a major public health problem that threatens the well-being of older adults and has been neglected and underfunded.

Earlier this week, the Secretary of the Department of Health and Human Services Xaiver Becerra and coauthors wrote an article about the nation's behavioral health crisis and the HHS roadmap to address it.

Enjoying Forefront articles? Bookmark our website to never miss an update.

Advertisement
Will Naloxone Become An Over-The-Counter Drug?

Listen to Leslie Erdelack and Jessica Bylander discuss the FDA's look into the potential for over-the-counter naloxone products to help reduce opioid overdose deaths.

Daily Digest
Facebook
 
Twitter
 
Linkedin
 
Youtube
 
Email
About Health Affairs

Health Affairs is the leading peer-reviewed journal at the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.  

Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States

Privacy Policy

To unsubscribe from this email, update your email preferences here
.